Canaccord Genuity Group Lowers Voyager Therapeutics (NASDAQ:VYGR) Price Target to $12.00

Voyager Therapeutics (NASDAQ:VYGR) had its price objective decreased by analysts at Canaccord Genuity Group from $14.00 to $12.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 207.69% from the company’s previous close.

Other analysts have also issued research reports about the company. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an “overweight” rating in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday. Citigroup started coverage on Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target for the company. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $14.86.

Voyager Therapeutics Price Performance

Shares of VYGR opened at $3.90 on Thursday. Voyager Therapeutics has a one year low of $3.56 and a one year high of $10.66. The firm has a market capitalization of $213.04 million, a P/E ratio of 5.49 and a beta of 0.99. The business has a fifty day moving average of $4.88 and a 200 day moving average of $5.85.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. During the same period in the previous year, the firm earned $1.25 EPS. Analysts expect that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Over the last three months, insiders have sold 10,778 shares of company stock worth $58,548. Corporate insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Empowered Funds LLC raised its holdings in shares of Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after buying an additional 2,278 shares during the period. Rhumbline Advisers raised its holdings in shares of Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock worth $405,000 after buying an additional 2,354 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Voyager Therapeutics by 3.7% in the fourth quarter. Wells Fargo & Company MN now owns 66,718 shares of the company’s stock worth $378,000 after buying an additional 2,400 shares during the period. Picton Mahoney Asset Management raised its holdings in shares of Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after buying an additional 2,444 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after buying an additional 3,077 shares during the period. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.